Search
RgenX Medicines' Universal iPSC-Derived Parkinson's Disease Cell Therapy Receives FDA Fast Track Designation
2025-08-18 /
Read about 0 minute
Author：小编
Independently developed by RgenX Yilian Pharmaceutical Technology (Chengdu) Co., Ltd., the NouvNeu001 injection represents a groundbreaking universal therapeutic drug derived from induced pluripotent stem cells (iPSCs) for the treatment of Parkinson's disease. The U.S. Food and Drug Administration (FDA) has granted this product Fast Track Designation, paving the way for its expedited development and approval process. Furthermore, the FDA has authorized an expansion in its use. This latest milestone follows a special exemption granted to NouvNeu001 in March 2024, underscoring RgenX Medicines' significant advancements in the realm of cell therapy for Parkinson's disease.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
